Vela purchased Great Basin for $1.4 million in June, and will reopen its Utah-based lab, rehire employees, and commercialize the firm's infectious disease platform.
Locus said it will pair the EpiBiome platform with its own CRISPR-based synthetic biology system to develop products that can edit the microbiome.
JPK provides microscopy instrumentation for biomolecular and cellular imaging, as well as force measurements on single molecules, cells, and tissues.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.
Through the deal, Precision Therapeutics will acquire the 75 percent stake in Helomics that it does not already own.
Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.
Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.
With its purchase of decision support technology maker Interactive Biosoftware, Sophia looks to extend its AI platform deeper into NGS interpretation.
The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.
Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.
Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.
Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.
In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.